BMO Capital Initiates Coverage on Five Prime Therapeutics Inc(NASDAQ:FPRX). The shares have been rated Market Perform. The rating by BMO Capital was issued on Apr 12, 2016.
In a different note, On Mar 11, 2016, Credit Suisse said it Maintains its rating on Five Prime Therapeutics Inc. In the research note, the firm Lowers the price-target to $54.00 per share. The shares have been rated ‘Outperform’ by the firm. Credit Suisse said it Initiates Coverage on Five Prime Therapeutics Inc, according to a research note issued on Jan 20, 2016. In the research note, the firm Announces the price-target to $54 per share. The shares have been rated ‘Outperform’ by the firm.
Five Prime Therapeutics Inc (FPRX) shares turned negative on Fridays trading session with the shares closing down -0.75 points or -1.58% at a volume of 6,18,696. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $48. The peak price level was also seen at $48 while the days lowest was $46.31. Finally the shares closed at $46.6. The 52-week high of the shares is $48.04 while the 52-week low is $14.7. According to the latest information available, the market cap of the company is $1,296 M.
Five Prime Therapeutics Inc(FPRX) last announced its earnings results on Mar 10, 2016 for Fiscal Year 2015 and Q4.Company reported revenue of $363.34M. Analysts had an estimated revenue of $354.16M. Earnings per share were $10.63. Analysts had estimated an EPS of $9.67.
Several Insider Transactions has been reported to the SEC. On Apr 8, 2016, Marc Belsky (Senior Vice President and CFO) sold 20,814 shares at $45.04 per share price.Also, On Apr 7, 2016, Lewis T Williams (President, CEO and Chairman) sold 52,801 shares at $43.08 per share price.On Jan 29, 2016, Francis Willard Sarena (EVP, Gen Counsel & Secretary) sold 30,000 shares at $35.31 per share price, according to the Form-4 filing with the securities and exchange commission.
Five Prime Therapeutics Inc. (Five Prime) is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include FPA008 FPA144 and FP-1039/GSK3052230. FPA008 is an antibody that inhibits colony stimulating factor-1 (CSF1) receptor (CSF1R) that the Company is developing in rheumatoid arthritis. FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b (FGFR2b) which the Company is developing to treat patients with gastric cancer. FP-1039/GSK3052230 is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors (FGFs) involved in cancer cell proliferation and new blood vessel formation. Its partner GlaxoSmithKline is developing FP-1039/GSK3052230 to treat patients with squamous non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma.